Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma.
Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma.
复制标题
FGFR3-TACC3 融合阳性转移性尿路上皮癌患者对 FGFR3 抑制的连续反应以及随后对 Atezolizumab 的异常反应。
DOI：
10.1200/po.18.00117
复制
发表时间：
2018
影响因子：
4.6
通讯作者：
Bellmunt,Joaquim
中科院分区：
文献类型：
--
作者：
Nassar,AminH;Lundgren,Kevin;Kim,Jaegil;Choueiri,ToniK;Sonpavde,GuruP;Kwiatkowski,DavidJ;Bellmunt,Joaquim
